In This Section      
 

ACGME Core Faculty

Our division consists of more than 70 faculty members, many of whom work closely with our fellows on the wards and as research mentors. The following are a few examples of our wonderful faculty who are dedicated to nurturing the clinical skills and professional development of our fellows.

Paul Auwaerter, MD

Dr. Paul Auwaerter is a professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include Lyme disease, Epstein-Barr virus and fever of unknown origin. Dr. Auwaerter serves as the clinical director of the Division of Infectious Diseases. He is also the director of the Fisher Center for Environmental Infectious Diseases and the chief medical officer of the Point of Care-Information Technology (POC-IT) CenterHe earned his M.D. from the Columbia University College of Physicians and Surgeons. His research interests include tick-borne diseases and point of care information technology. Dr. Auwaerter serves on the Clinical Compensation Subcommittee for the Johns Hopkins Department of Medicine. He was recognized with a Healthnetworks Service Excellence Award in 2014. He is a member of the American Society of Microbiology and the Infectious Diseases Society of America.


Robin Avery, MD

Dr. Robin Avery is an infectious disease physician who joined the Johns Hopkins faculty in 2012, with two decades of experience in transplant infectious disease. She is a past chair of the American Society of Transplantation (AST) Infectious Disease Community of Practice, was a co-editor of the first edition of the AST ID Guidelines, and serves on a Guidelines Committee for the Infectious Disease Society of America (IDSA) on immunizations in the immunocompromised host. She was the founding head of the Transplant Infectious Disease Section at the Cleveland Clinic and served as the founding director of the Cleveland Clinic Transplant ID Special Fellowship, authoring a curriculum that served as the basis for curricula later endorsed by the AST and IDSA. Her clinical and research interests include pre-transplant donor and recipient evaluation, and prevention and treatment of post-transplant infections, particularly transplant-associated viruses, viral load monitoring, novel therapies for CMV, hypogammaglobulinemia, immunizations, and strategies for safer living post-transplant. She has a strong interest in patient education and co-authored the script for a video designed to educate patients on decreasing post-transplant infection risks.

 


Kelly Gebo, MD

Dr. Kelly Gebo is a graduate of The Johns Hopkins University School of Medicine. She also earned an MPH in Epidemiology from The Johns Hopkins Bloomberg School of Public Health. She completed residency training in Internal Medicine at The Johns Hopkins Hospital followed by two years of fellowship training as a Robert Wood Johnson Clinical Scholar in the Department of Medicine, also at Hopkins. Her clinical and research interests include evidence based practice, health disparities in access to care, health utilization, HIV and aging, hepatitis, outcomes research, and policy generation.

Dr. Gebo is affiliated with The Johns Hopkins Center for Global Health, Reducing Global Inequities in Burden of Disease, where she has translated individual patient care to larger global health issues. As part of a multidisciplinary group in Baltimore, she has been closely involved with mentoring students interested in global health issues as it relates to infectious diseases. She worked closely with students engaged in research projects such as Cancer in the Hopkins HIV Cohort in the Era of HAART and the Impact of Illicit Drug Use and Substance Abuse Treatment on HAART Adherence. Her work with HIV in the Elderly Population was recently supported by an RO1 Research Grant from the National Institute on Aging, entitled "Clinical Outcomes in Elderly HIV Patients." A pilot grant in 2003 provided funds for her to study National Trends in HIV+ Hospitalizations 1996-2000.

Dr. Gebo has authored or co-authored more than forty-two publications.


Susan Anne Tuddenham, M.D., M.P.H.

Dr. Susan Tuddenham is an assistant professor of medicine at the Johns Hopkins University School of Medicine.

She received her M.P.H. from the Johns Hopkins Bloomberg School of Public Health and her M.D. from the David Geffen School of Medicine at UCLA. She completed her residency in internal medicine and her fellowship in infectious diseases at the Johns Hopkins Hospital.

Her research interests are in sexually transmitted infections, HIV, and the human microbiome in the context of infectious diseases.

Her outpatient clinical practice focuses on recurrent vaginitis (including Bacterial Vaginosis and Vulvovaginal Candidiasis), Sexually Transmitted Infections, recurrent Urinary Tract Infections and HIV.


Stuart Ray, MD

Stuart C. Ray, MD, FACP, FIDSA serves as Vice Chair of Medicine for Data Integrity and Analytics and is a Professor in the Division of Infectious Diseases within the Department of Medicine, with secondary appointments in Viral Oncology and Health Sciences Informatics. He is Scientific Director of the JHU Laboratory for Integrated NanoDiagnostics, directs the virology laboratory and is a clinical investigator in the Center for Viral Hepatitis Research in the Division of Infectious Diseases. He is a faculty member of the Graduate Immunology program, the Graduate Pharmacology program, and of the Janeway Firm of the Osler Medical Service.

Dr. Ray received his M.D. from Vanderbilt University School of Medicine in 1990. After an internship and residency at Johns Hopkins Hospital, he continued there as an Assistant Chief of Service and fellow in Infectious Diseases. During his fellowship, he studied the immunology and sequence variation of HIV in the laboratory of Dr. Robert Bollinger. During that time, he developed an interest in HIV sequence variation during antiretroviral therapy in a productive collaboration with Dr. Robert Siliciano that continues to the present.

In 1997 Dr. Ray joined the Johns Hopkins faculty, and under the mentorship of Dr. David Thomas shifted his primary research focus to hepatitis C virus (HCV).  His laboratory work has focused on the sequence variation of HCV during acute and chronic infection, developing and applying computational and molecular biology tools to underlying mechanisms including stochastic variation, immune selection, and viral fitness. He continues to care for patients with HIV, HCV, and other infectious diseases.


Cynthia L. Sears, MD

My laboratory focuses on the pathogenesis of colon disease by enteric bacteria using enterotoxigenic Bacteroides fragilis (ETBF) as a model for inducing colon inflammation. We identified the B. fragilis toxin gene (bft), purified the protein (BFT) and defined its mechanism of action in vitro. More recently, we established in vivo models of ETBF colitis and colon tumorigenesis. Using these models, we have identified that ETBF induce selective Stat3/Th17 immune responses in the colon and that these pathways, at least in part, contribute to colon tumorigenesis. Our data were the first to report this mechanism for inflammation-induced endogenous colon tumor induction in response to colon colonization with a human commensal (up to 40% of ETBF-colonized humans are asymptomatic). We are extending this work to human studies to understand the microbial contribution to colitis and colon cancer pathogenesis. Our studies include the molecular mechanisms by which BFT and ETBF induce colon carcinogenesis including identifying the BFT receptor, defining BFT-induced activation of colonic epithelial signaling pathways, determining the immunologic  determinants  of  colon  carcinogenesis  and  establishing  the  genetic  and  epigenetic mutations contributing to colon tumor induction and promotion stimulated by ETBF through BFT.


Jonathan Zenilman, MD

Dr. Jonathan M. Zenilman is a professor of medicine, dermatology and obstetrics and gynecology at the Johns Hopkins University School of Medicine. He also has as joint appointments in population family and reproductive health, international health and epidemiology at the Johns Hopkins University Bloomberg School of Public Health.

Dr. Zenilman is known internationally for his work in infectious disease epidemiology. Prior to coming to Johns Hopkins in 1989, he was a medical epidemiologist at the U.S. Centers for Disease Control (CDC) where he conceived, developed and implemented the National Gonococcal Isolate Surveillance Program (GISP). GISP operated continuously since 1987, and has been responsible for identifying multiple types of resistant strains before they became large clinical problems. He also coordinated and wrote the 1989 STD Treatment Guidelines.

He became chief of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center in 2003. Under his leadership, the Bayview division has increased from 1.5 to 9 faculty members, and developed major clinical and research programs in STIs, hospital epidemiology, antibiotic stewardship and skin and soft tissue infections. Bayview has also become a center for Phase 1 through Phase 3 clinical trials for new antimicrobials and wound care products. Dr. Zenilman is well known for his work ascertaining the validity (or non-validity) of self-reported condom use, for further understanding of the interactions between STDs and HIV infection, and policy work on national and international levels.

Dr. Zenilman has nearly 300 publications and is an active teacher, mentoring more than 40 fellows and residents during his career.